Abstract:Abstract Background Anti-nerve growth factor (NGF) monoclonal antibodies (anti-NGF mAbs) have been reported to significantly attenuate pain, but the mechanism involved has not been fully elucidated, and the serious adverse events associated with mAbs seriously limit their clinical use. This study further investigated the mechanism by which peripheral NGF is involved in neuropathic pain and found safe, natural compounds that target NGF to attenuate neuropathic pain. Methods Nociception was assessed by the Von Frey hair and Hargreaves’ methods. Western-blotting, qPCR and immunofluorescence were used to detect the cell signaling pathway. RAW264.7 macrophages and RSC96 Schwann cells were cultured for in vitro evaluation. Results Intraplantar administration of anti-NGF mAbs suppressed the expression of phosphorylated transforming growth factor-β-activated kinase 1 (TAK1) in the dorsal root ganglion (DRG) and sciatic nerve. Intraplantar administration of a TAK1 inhibitor attenuated CCI-induced neuropathic pain and suppressed the expression of phosphorylated mitogen-activated protein kinases (MAPKs) in the DRG and sciatic nerve. Perisciatic nerve administration of levo- corydalmine ( l- CDL) on the operated side obviously attenuated CCI-induced neuropathic pain and suppressed the expression of mNGF and proNGF. In addition, l -CDL-induced antinociception was reversed by intraplantar administration of NGF. Further results indicated that l- CDL-induced suppression of phosphorylated TAK1, MAPKs, and p65 and expression of the proinflammatory cytokines TNF-α and IL-1β in the DRG and sciatic nerve were all abolished by NGF. In addition, in vitro experiments indicated that l- CDL suppressed the secretion of NGF and proNGF in RAW264.7 macrophages and RSC96 Schwann cells, which was abolished by AP-1 and CREB agonists, respectively. Conclusions This study showed NGF inhibition suppressed TAK1 in the periphery to attenuate CCI-induced neuropathic pain through inhibition of downstream MAPK and p65 signaling. The natural compound l- CDL inhibited NGF secretion by macrophages and Schwann cells and downstream TAK1-MAPK/NF-κB signaling in the periphery to attenuate CCI-induced neuropathic pain. Graphical abstract Proposed mechanisms underlying the effect of l -CDL in periphery of CCI rats. In CCI rats, macropahages and Schwann cells could secret NGF to act on the receptors in the periphery to activate TAK1-MAPK/NF-κB axis and promote the release of proinflammatory cytokines, including TNF-α and IL-1β to promote neuropathic pain. l -CDL decreased the secretion of NGF through inhibiting AP-1 and CREB respectively in RAW264.7 and RSC96 Schwann cells to attenuate CCI-induced neuropathic pain by inhibiting the TAK1-p38 MAPK/NF-κB signaling pathway.

Penehyclidine Hydrochloride Suppressed Peripheral Nerve Injury-Induced Neuropathic Pain by Inhibiting Microglial MAPK/p-p38/IL-1β Pathway Activation

Penehyclidine hydrochloride suppressed peripheral nerve injury-induced neuropathic pain by inhibiting microglial MAPK/p-p38/IL-1 β pathway activation

Penehyclidine Hydrochloride Attenuates LPS-induced Acute Lung Injury Involvement of NF-kappaB Pathway.

Delayed Inhibition of ERK and P38 Attenuates Neuropathic Pain Without Affecting Motor Function Recovery after Peripheral Nerve Injury.

Intrathecal Administration of Clonidine Attenuates Spinal Neuroimmune Activation in A Rat Model of Neuropathic Pain with Existing Hyperalgesia

Intrathecal Infusion of Pyrrolidine Dithiocarbamate for the Prevention and Reversal of Neuropathic Pain in Rats Using a Sciatic Chronic Constriction Injury Model.

Paeonol alleviates neuropathic pain by modulating microglial M1 and M2 polarization via the RhoA/p38MAPK signaling pathway

Suppression of peripheral NGF attenuates neuropathic pain induced by chronic constriction injury through the TAK1-MAPK/NF-κB signaling pathways

Influence of Intrathecal Injection of P38 MAPK Inhibitor on BDNF Expression in Dorsal Horn of Spinal Cord of Rats with Neuropathic Pain

Pharmacological Inhibition of CXCR2 Alleviates Neuropathic Pain by Inactivating Microglia in a Rat L5 Spinal Nerve Ligation Model.

Neuroprotective effects of penehyclidine hydrochloride against cerebral ischemia/reperfusion injury in mice.

Inhibition of apoptosis signal-regulating kinase by paeoniflorin attenuates neuroinflammation and ameliorates neuropathic pain

Attenuating Phosphorylation of P38 MAPK in the Activated Microglia: A New Mechanism for Intrathecal Lidocaine Reversing Tactile Allodynia Following Chronic Constriction Injury in Rats

Analgesic Effect of Intrathecal APA Microcapsulized NIH3T3/rPENK on Neuropathic Pain Induced by CCI in Rats

Post-injury Administration of Minocycline: an Effective Treatment for Nerve-Injury Induced Neuropathic Pain

Effects of ketamine on spinal nerve ligation-induced neuropathic pain

Propofol Alleviates Neuropathic Pain Induced by Chronic Contractile Injury by Regulating the Spinal glun2b-p38mapkepac1 Pathway

Penehyclidine Hydrochloride Decreases Pulmonary Microvascular Endothelial Inflammatory Injury Through a Beta-Arrestin-1-Dependent Mechanism.

Hyperbaric Lidocaine Aggravates Diabetic Neuropathic Pain by Targeting p38 MAPK/ERK and PINK1/Parkin-Mediated Mitophagy Signaling Pathway

The effect of intrathecal administration of glial activation inhibitors on dorsal horn BDNF overexpression and hind paw mechanical allodynia in spinal nerve ligated rats

Neohesperidin Alleviates the Neuropathic Pain Behavior of Rats by Downregulating the P2X4 Receptor